Lesinurad: A significant advancement or just another addition to existing therapies of gout?
Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more potent urate-lowering therapies for treating patients inadequately controlled with available drugs. Lesinurad in combination with a xanthine oxidase inhibitor provides an effective mode of therapy in the management of hyperuricemia associated with gout. Lesinurad is a selective uric acid transporter 1 (URAT1) inhibitor. URAT1 is responsible for the majority of uric acid absorption from kidneys to the circulation. Lesinurad was granted marketing approval based on three randomized, double-blind, placebo-controlled; phase III clinical trials. It is devoid of interaction with organic anion transporters (OATs) such as OAT1 and 3, responsible for drug-drug interactions, an undesirable property associated with probenecid. On-going research is more focused on reducing inflammation consequent to deposition of crystals rather than production and excretion of urate. Various targets are being explored, and interleukin-1 beta inhibition seems to be one of the most promising approaches.
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Ajay
A
Gupta
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Pramod Kumar
PK
Sharma
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Arup Kumar
AK
Misra
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Surjit
S
Singh
Hyperuricemia; lesinurad; uric acid transporter 1; xanthine oxidase inhibitor